3 recruiting, 1 completed. 4 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Recruiting 3, Completed 1 |
| Phase 2 | 3 | Recruiting 3 |
Follow Rescue Medications: new trials by email Literature Review of Rescue Medications trials Research Report on Rescue Medications
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) MK-1084, Patritumab deruxtecan, Sacituzumab tirumotecan - Lung Neoplasm Malignant | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 140 | 2026-04-30 | 2026-10-01 |
| A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) Gocatamig, I-DXd, Atezolizumab - Small Cell Lung Cancer Extensive Stage | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 170 | 2026-01-29 | 2026-10-20 |
| Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) Ramucirumab, Paclitaxel, Sacituzumab Tirumotecan - Gastroesophageal Junction, Gastroesophageal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 210 | 2024-08-07 | 2026-09-03 |
| A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001) MK-6837, Pembrolizumab, Rescue Medications - Neoplasm Metastasis | Phase 1 | Completed | Merck Sharp & Dohme LLC | 40 | 2024-07-14 | 2026-08-28 |
Parkinson Disease 4, Autosomal Dominant Lewy Body (2) · Esophageal Neoplasms (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1)
United States (4) · Chile (3) · China (3) · Germany (3) · Israel (3) · Italy (3) · South Korea (3) · Brazil (2) · Greece (2) · Spain (2) · Argentina (1) · Australia (1) · Canada (1) · France (1) · Hong Kong (1)
2023 (1), 2025 (1)